Kensington, MD, USA and Munich/Martinsried, Germany, March 05, 2026 (GLOBE NEWSWIRE) -- Galimedix Therapeutics to present ...
Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results